HR POSITIVE/HER2 LOW BREAST CANCER
Clinical trials for HR POSITIVE/HER2 LOW BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER2 LOW BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER2 LOW BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat breast cancer before surgery
Disease control Not yet recruitingThis phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infu…
Matched conditions: HR POSITIVE/HER2 LOW BREAST CANCER
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could two new drugs boost chemo success in HER2-Low breast cancer?
Disease control Not yet recruitingThis phase II trial tests whether adding the drugs SHR-A1811 and/or adebrelimab to standard chemotherapy can improve outcomes for people with HR-positive, HER2-low early-stage breast cancer. About 249 participants will receive either chemo alone, chemo plus adebrelimab, or a sequ…
Matched conditions: HR POSITIVE/HER2 LOW BREAST CANCER
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC